MAP2K7 and melanoma: While BRAF/MEK inhibitor combination therapy is well established in patients with V600E/K mutations, the clinical data for the ~5% of melanomas with non-V600 BRAF mutations mainly consists of case reports given their rarity and genetic heterogeneity.